Discover the Power of
GLP-1 Weightloss Management
At Viona Medical Spa
At Viona Medical Spa, we’re excited to offer advanced solutions to support your weight loss journey. GLP-1 receptors, like Semaglutide and Tirzepatide, represent a groundbreaking approach to achieving sustainable weight loss. These innovative medications, backed by extensive clinical research, work by harnessing your body’s natural systems to help you feel fuller longer, reduce cravings, and achieve meaningful results.
Tirzepatide and Semaglutide are highly effective medications for weight management.
Among adults, once-weekly treatment with Semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone.
Learn more about Semaglutide and Tirzepatide below!
Semaglutide
-
Semaglutide is a selective GLP-1 receptor, administered once weekly via subcutaneous injection. It mimics the GLP-1 hormone, which is secreted by the gut post-meal to regulate appetite and metabolism. Semaglutide slows gastric emptying, reduces hunger, and makes you feel fuller longer by acting on GLP-1 receptors in the brain, particularly the hypothalamus. It also decreases glucagon secretion, which may indirectly support weight loss by altering energy metabolism.
-
Semaglutide reduces appetite by signaling fullness to the brain, decreasing food intake. It slows gastric emptying, prolonging fullness after meals, and suppresses hunger signals, helping patients adhere to reduced-calorie diets. Its effects on the brain’s reward system may also reduce food cravings. Clinical data suggest semaglutide’s weight loss is primarily driven by reduced energy intake, with no significant changes in energy expenditure noted in trials.
-
Semaglutide is highly effective for obesity management, achieving mean weight losses of 15–17% in clinical trials. In the SURMOUNT-5 trial, it resulted in a 13.7% weight reduction at 72 weeks, with 60.5% of participants losing at least 10% and 27.3% losing 20% or more.. Semaglutide reduced waist circumference by 13.0 cm, reflecting significant fat loss
Tirzepatide
-
Tirzepatide is a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is a 39-amino-acid synthetic peptide with a half-life of approximately 7 days, allowing once-weekly subcutaneous administration. By activating both GLP-1 and GIP receptors, tirzepatide mimics incretin hormones that regulate appetite and energy balance. It reduces hunger, increases satiety, and slows gastric emptying, leading to decreased food intake. Additionally, it may enhance energy expenditure and fat metabolism, contributing to weight loss.
-
Tirzepatide suppresses appetite by acting on hypothalamic regions that regulate hunger and fullness, reducing food cravings and promoting a negative energy balance. It slows gastric emptying, prolonging feelings of fullness, and may increase fat oxidation.
-
Clinical trials demonstrate tirzepatide’s superior efficacy for weight reduction in adults with obesity. In the SURMOUNT-5 trial, tirzepatide resulted in a mean weight loss of 20.2% at 72 weeks, with 80% of participants achieving at least 10% weight loss and nearly 50% reaching 20% or more. Another study reported mean weight losses of 15%, 19.5%, and 20.9% for 5 mg, 10 mg, and 15 mg doses, respectively, compared to 3.1% for placebo at 72 weeks. Tirzepatide also reduced waist circumference by 18.4 cm, indicating significant fat mass reduction.
Interested in starting GLP-1’s?
Fill out this form or click Book Now below!
